Merck moves ahead with large trials for Alzheimer's drug
This article was originally published in Scrip
Executive Summary
Merck & Co is moving ahead with two large late-stage studies for its Alzheimer’s drug after getting a clearance from the independent monitors who deemed the therapy safe.